<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600208</url>
  </required_header>
  <id_info>
    <org_study_id>BT13BTθ51</org_study_id>
    <nct_id>NCT02600208</nct_id>
  </id_info>
  <brief_title>Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device</brief_title>
  <official_title>BT13BTθ51 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha Beta T Cell and B Cell Depletion For Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Julie-An M. Talano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Miltenyi Biotec, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm pilot study for patients with hematologic malignancies with alternative
      donor sources receiving unrelated or partially matched related/Haploidentical mobilized
      peripheral stem cells (PSCs) using the CliniMACS system for Alpha Beta T cell depletion plus
      CD19+ B cell depletion to determine efficacy as determined by engraftment and GVHD, and one
      year leukemia free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to evaluate a new method of T cell depletion using the
      Miltenyi CliniMACS™ device for patients undergoing a peripheral stem cell transplant
      utilizing either a unrelated donor or partially matched/haploidentical related donor. This
      new method is called α/β (alpha/beta) T cell depletion and CD19+ B cell depletion. This pilot
      study will evaluate if this new method of T cell and B cell depletion is a more effective way
      of removing T cells thus reducing the risk of severe acute and chronic GVHD and result in a
      durable engraftment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the engraftment of patients receiving unrelated donor or partially matched related donor peripheral stem cells that have T cell depleted and CD19+ B cell depleted using the CliniMACS device.</measure>
    <time_frame>DAY 42</time_frame>
    <description>Engraftment will be defined using the standard CIBMTR definition of ANC &gt;500 for the first of 3 consecutive days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the probability of one year leukemia free survival (LFS).</measure>
    <time_frame>1 year</time_frame>
    <description>Leukemia relapse is defined as presence of malignant cells in the blood or other body site after initiation of conditioning in a patient previously in remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the incidence and extent of acute and chronic graft vs. host disease.</measure>
    <time_frame>1 year</time_frame>
    <description>Acute GVHD will be graded using the standard Glucksberg grading system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the incidence treatment-related mortality (TRM).</measure>
    <time_frame>1 year</time_frame>
    <description>TRM is defined as death from non-disease related causes in the 100 days from stem cell infusion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Single Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha Beta T cell depletion is performed for all PBSC grafts using the CliniMACs device</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CliniMACs</intervention_name>
    <description>Depletion of Alpha Beta T cells in the PBSC graft</description>
    <arm_group_label>Single Experimental Arm</arm_group_label>
    <other_name>Alpha/Beta T-Cell Depletion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient:

          1. Age. Patient age &lt; 23 years. Both genders and all races eligible.

          2. Disease eligibility

        Leukemias/lymphomas:

          -  Acute myeloid leukemia, primary or secondary

          -  Disease status: remission or &lt;10% bone marrow blasts

          -  Myelodysplasia

          -  Acute lymphoblastic leukemia

          -  Disease status: in hematologic remission

          -  Chronic myelogenous leukemia:

          -  Disease status: chronic phase, accelerated phase or blast crisis now in second chronic
             phase.

          -  Mixed lineage or biphenotypic acute leukemia

          -  Lymphoblastic lymphoma

          -  Disease status: remission

          -  Burkitt's lymphoma/leukemia:

          -  Disease status: in remission

        Exclusion Criteria:

          -  Patient

               1. Patients who do not meet disease, organ or infectious criteria.

               2. No suitable donor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie-An Talano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelly LeVeque, RN</last_name>
    <phone>414-266-6471</phone>
    <email>mleveque@chw.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly LeVeque, RN</last_name>
      <phone>414-266-6471</phone>
      <email>mleveque@chw.org</email>
    </contact>
    <contact_backup>
      <last_name>Adam Fiebelkorn, CCRP</last_name>
      <phone>414-266-2137</phone>
      <email>afiebelk@mcw.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Julie-An M. Talano</investigator_full_name>
    <investigator_title>Associate Professor - Department of Pediatrics - Division of Hematology/Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

